Asia-Pacific EPO drugs market would be the most potential market among other regions

29/dic/2020 07:00:18 Automotive Market Research Reports Contatta l'autore

Questo comunicato è stato pubblicato più di 30 giorni fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Globally, ~70% of the market share is held by the developed regions owing to favorable reimbursements leading to affordability for EPO drugs. Going forward, owing to commercialization of EPO biosimilars, the Asia-Pacific EPO drugs market would be the most potential market among other regions.

Global Erythropoietin Drugs Market is expected to garner $11.9 billion by 2020, registering CAGR of 9.7% during the forecast period 2014 – 2020.

Key findings of Erythropoietin Drugs Market:

  • Europe led the global EPO drug market in 2013 closely followed by North America
  • Asia Pacific EPO drugs market is projected to grow at a CAGR of 13.3% during the forecast period, fastest among the four geographies
  • Currently, Anemia therapeutics (Cancer and HIV treatment) market leads the overall EPO drugs market; however, kidney therapeutic segment would emerge as the largest market segment by 2020
  • Originator companies are investing in R&D for expanding product i.e. EPO drug applications to newer disorders such as neural diseases and in wound healing
  • EPO drugs market is witnessing high commercialization of biosimilars for the ‘off-patent’ drug namely Erythropoietin alfa

The first EPO drug – Epogen (Erythropoietin alfa), launched by Amgen, has witnessed patent expiry in 2014. Following this, a number of biosimilar Erythropoietin alfa have been launched by major companies such as Biocon, Ranbaxy, Emcure Pharmaceuticals. In addition, Amgen currently owns the patent Aranesp for Darbepoetin alfa; which is expected to expire by 2016, thus, calling for launch of Darbepoetin Alfa biosimilars. Some of leading players operating in EPO drug market are Amgen Inc., Johnson & Johnson, Roche, LG Life Sciences Ltd., Biocon, Intas Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Ranbaxy Laboratories Ltd., and Celltrion, Inc.

GEOGRAPHY

  • North America
  • Europe
  • Asia-Pacific
  • LAMEA

Read More: https://www.alliedmarketresearch.com/press-release/global-erythropoietin-drugs-market-is-expected-to-reach-11-9-billion-by-2020-allied-market-research.html

blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl